Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Editas Medicine, Inc. on June 15, 2017. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters.
Material Changes
There are no material financial changes reported in this filing. The primary events are the election of directors and the ratification of the independent auditor.
Corporate Governance and Voting Results
Director Elections
Stockholders elected three Class I directors to serve until the 2020 Annual Meeting:
- Alexis Borisy: 27,260,178 votes for; 2,527,788 votes withheld.
- Douglas G. Cole, M.D.: 21,170,358 votes for; 8,617,608 votes withheld.
- Akshay K. Vaishnaw, M.D., Ph.D.: 29,739,543 votes for; 48,423 votes withheld.
There were 6,791,370 broker non-votes for each director candidate.
Auditor Ratification
Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm.
- Votes For: 36,467,338
- Votes Against: 37,627
- Abstaining: 74,371
- Non-Votes: 0
Investor Verification Checklist
- Verify the tenure of the newly elected Class I directors (through 2020).
- Confirm the continued engagement of Ernst & Young LLP as the independent auditor.
- Note the significant number of broker non-votes (6,791,370) regarding director elections, which may indicate shares held in street name where brokers lacked discretionary voting authority.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.